Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Cancer Science

Volumn 104, Issue 1, 2013, Pages 105-110

  Ogura, Michinori ^a   Tobinai, Kensei ^b   Hatake, Kiyohiko ^c   Uchida, Toshiki ^a   Suzuki, Tatsuya ^a   Kobayashi, Yukio ^b   Mori, Masakazu ^b   Terui, Yasuhito ^c   Yokoyama, Masahiro ^c   Hotta, Tomomitsu ^d  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OBINUTUZUMAB;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; B CELL LYMPHOMA; BACKACHE; CANCER RECURRENCE; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPERBILIRUBINEMIA; HYPOPHOSPHATEMIA; INFUSION RELATED REACTION; INSOMNIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; JAPAN; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RECURRENCE; YOUNG ADULT;

EID: 84872264814     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12040     Document Type: Article

References (24)

1. Coiffier B, Lepage E, Brière J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
2. Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-32.
3. Pfreundschuh M, Trümper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-91.
4. Marcus R, Imrie K, Solal-Céligny P et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579-86.
5. Hallek M, Fischer K, Fingerle-Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-74.
6. van Oers MH, Van Glabbeke M, Giurgea L et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28: 2853-8.
7. Salles G, Seymour JF, Offner F et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42-51.
8. Glennie MJ, French RR, Cragg MS et al. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44: 3823-37.
9. Chan HT, Hughes D, French RR et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 2003; 63: 5480-9.
10. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004; 103: 2738-43.
11. Niederfellner G, Lammens A, Mundigl O et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011; 118: 358-67.
12. Ivanov A, Beers SA, Walshe CA et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009; 119: 2143-59.
13. Alduaij W, Ivanov A, Honeychurch J et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011; 117: 4519-29.
14. Mössner E, Brünker P, Moser S et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115: 4393-402.
15. Patz M, Isaeva P, Forcob N et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol 2011; 152: 295-306.
16. Dalle S, Reslan L, Besseyre de Horts T et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 2011; 10: 178-85.
17. Salles G, Morschhauser F, Lamy T et al. Efficacy and safety of obinutuzumab (GA101) monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma: results from a phase I/II study (BO20999). Blood 2011; 118: Abstract 268.
18. Sehn L, Goy A, Offner FC et al. Randomized phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin's lymphoma: preliminary analysis of the GAUSS study. Blood 2011; 118: Abstract 269.
19. Radford J, Davies A, Cartron G et al. Obinutuzumab (GA101) in combination with FC or CHOP in patients with relapsed or refractory follicular lymphoma: final results of the Phase I GAUDI study (BO21000). Blood 2011; 118: Abstract 270.
20. Morschhauser F, Cartron G, Thieblemont C et al. Encouraging activity of obinutuzumab (GA101) monotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma: results from a phase II study (BO20999). Blood 2011; 118: Abstract 3655.
21. Salles G, Morschhauser F, Lamy T et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012; 119: 5126-32.
22. Sehn L, Assouline SE, Stewart DA et al. A phase I study of obinutuzumab induction followed by two years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 2012; 119: 5118-25.
23. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
24. Ogura M, Morschhauser F, Tobinai K et al. Comparison of single agent GA101 in Japanese and European patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) - Results from two phase I studies. Blood 2010; 116: Abstract 4921.